DigiWest® for Preclinical Drug Development

Dr. Markus Templin
Group Leader Cell- and Molecular Biology
+49 7121 51530-828
E-Mail

With DigiWest®, you are now able to screen signaling pathways on the protein level to spot out the changes caused by a compound. DigiWest® brings you a deep understanding of MoA, helps identify a lead compound, and gives you insights into potential side effects.

At NMI TT Pharmaservices, we have a long-standing track record in working with small, medium and big size pharma companies on single studies as well as extended workbench agreements. Contact us to establish cooperation with us.

DigiWest® for Compound Characterization

Case Study 1: DigiWest® for MoA studies

  • DigiWest® study identified AXIN1 as a mediator of a so far unknown Wnt response upon MEK inhibitor
Zhan T, et al. MEK inhibitors activate Wnt signaling and induce stem cell plasticity in colorectal cancer. Nature Communications 2019

Case Study 2: DigiWest® profiling in a PDX-based drug MoA study

  • HCC-PDX (patient-derived hepatocellular carcinoma xenograft) mouse models were treated with two different multikinase inhibitors
  • Pharmacodynamic analysis of drug response was done by DigiWest® using 116 antibodies
Kissel M, et al. Antitumor effects of [...] in preclinical models of hepatocellular carcinoma. Oncotarget 2017

Case Study 3: DigiWest® for compound profiling

  • HDAC (histone deacetylases) inhibitors are used in cancer treatments as they prevent the deacetylation of histone proteins. However, due to their wide biological actions, the MoA of HDAC inhibitors needs to be carefully investigated.
  • DigiWest® was used along mass spectrometry to assess the modifications of the acetylated proteome.
Mehul B, et al. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from [...] treated HuT78 CTCL cell line. Journal of Proteomics 2018

Case Study 4: DigiWest® Mode-of-action study for lead identification

  • Calu1 cells were treated with 1 MEK inhibitor vs. 1 PI3K inhibitor vs. 2 experimental lead compounds (data not shown) vs. DMSO. Cell samples were analyzed by DigiWest®, using 156 selected antibodies (total and phospho proteins) covering different signal transduction pathways.
  • DigiWest® yielded distinct signatures for each compound and allowed in-depth characterization of lead compounds as compared to reference drugs.

DigiWest® for Toxicology

Case Study 1: DigiWest® for toxicology assessment

  • DigiWest® reveals spatial differences in hepatic signaling upon CAR activation.
Treindl F, et al. Array-based Western-blotting reveals spatial differences in hepatic signaling and metabolism following CAR activation. Archives of Toxicology 2020

NMI Technologie Transfer GmbH
Markwiesenstraße 55, 72770 Reutlingen
Tel.: +49 7121 51530-0
Mail: info@nmi-tt.de

NMI on Social Media
Follow us now